Published in Curr Opin Biotechnol on August 20, 2011
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med (2012) 1.44
Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag. Angew Chem Int Ed Engl (2012) 1.25
Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS One (2014) 0.94
Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem (2011) 0.93
Bispecific antibodies and their applications. J Hematol Oncol (2015) 0.92
Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists. Proc Natl Acad Sci U S A (2015) 0.91
Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications. Int J Nanomedicine (2016) 0.91
Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies. FASEB J (2015) 0.87
Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A (2012) 0.87
Molecular approaches for improved clotting factors for hemophilia. Blood (2013) 0.85
In vitro selection of a peptide antagonist of growth hormone secretagogue receptor using cDNA display. Proc Natl Acad Sci U S A (2012) 0.84
The making of bispecific antibodies. MAbs (2017) 0.84
New developments in the management of moderate-to-severe hemophilia B. J Blood Med (2016) 0.82
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. MAbs (2013) 0.82
Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution. Biotechnol J (2014) 0.81
An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol (2016) 0.80
Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice. PLoS One (2014) 0.80
High-quality production of human α-2,6-sialyltransferase in Pichia pastoris requires control over N-terminal truncations by host-inherent protease activities. Microb Cell Fact (2014) 0.79
A platform for efficient, thiol-stable conjugation to albumin's native single accessible cysteine. Org Biomol Chem (2015) 0.78
Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery. Immunol Rev (2016) 0.78
An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. Proc Natl Acad Sci U S A (2014) 0.78
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. MAbs (2015) 0.78
Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci Rep (2014) 0.78
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody. PLoS One (2013) 0.78
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding. MAbs (2016) 0.77
Emerging and future therapies for hemophilia. J Blood Med (2015) 0.77
Site-specific fatty acid-conjugation to prolong protein half-life in vivo. J Control Release (2013) 0.77
Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility. Bioconjug Chem (2014) 0.77
Post-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies Infection. PLoS Negl Trop Dis (2016) 0.76
Studies to Prevent Degradation of Recombinant Fc-Fusion Protein Expressed in Mammalian Cell Line and Protein Characterization. Int J Mol Sci (2016) 0.76
The albumin-binding domain as a scaffold for protein engineering. Comput Struct Biotechnol J (2013) 0.76
Novel ubiquitin-derived high affinity binding proteins with tumor targeting properties. J Biol Chem (2014) 0.76
Site-Specific PEGylation of Therapeutic Proteins. Int J Mol Sci (2015) 0.76
Stoichiometry based steady-state hepatic flux analysis: computational and experimental aspects. Metabolites (2012) 0.76
Human plasma N-glycosylation as analyzed by MALDI-FTICR-MS associates with markers of inflammation and metabolic health. Mol Cell Proteomics (2016) 0.75
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A. Toxins (Basel) (2016) 0.75
Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B. Patient Prefer Adherence (2014) 0.75
The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life. PLoS One (2016) 0.75
Incorporation of heparin-binding proteins into preformed dextran sulfate-chitosan nanoparticles. Int J Nanomedicine (2016) 0.75
Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A. J Blood Med (2016) 0.75
Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. MAbs (2016) 0.75
Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon. ACS Chem Biol (2016) 0.75
Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget (2014) 0.75
Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment. Allergy (2013) 0.75
Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin. PLoS One (2014) 0.75
A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties. PLoS One (2015) 0.75
The development of bispecific antibodies and their applications in tumor immune escape. Exp Hematol Oncol (2017) 0.75
Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Sci Rep (2016) 0.75
FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes. PLoS One (2015) 0.75
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs (2016) 0.75
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev (2016) 0.75
A current perspective on applications of macrocyclic-peptide-based high-affinity ligands. Biopolymers (2016) 0.75
Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity. Br J Pharmacol (2016) 0.75
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging (2017) 0.75
In Vivo Evaluation of Site-Specifically PEGylated Chemically Self-Assembled Protein Nanostructures. Mol Pharm (2016) 0.75
Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
Immunoliposomes for cancer therapy. Curr Opin Mol Ther (2006) 0.88